Name | Recombinant Human PADI4 (N-6His) |
Purity | Greater than 95% as determined by reducing SDS-PAGE |
Endotoxin level | <1 EU/µg as determined by LAL test. |
Construction | Recombinant Human Protein-Arginine Deiminase Type-4 is produced by our E.coli expression system and the target gene encoding Met1-Pro663 is expressed with a 6His tag at the N-terminus. |
Accession # | AAH25718.1 |
Host | E.coli |
Species | Human |
Predicted Molecular Mass | 76.2 KDa |
Buffer | Supplied as a 0.2 μm filtered solution of 50mM Tris-HCl, 500mM NaCl, pH 7.5. |
Form | Liquid |
Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Protein-Arginine Deiminase Type-4; HL-60 PAD; Peptidylarginine Deiminase IV; Protein-arginine Deiminase type IV; PADI4; PADI5; PDI5
Background
Protein-Arginine Deiminase Type-4 (PADI4) belongs to the Protein Arginine Deiminase family. PADI4 is expressed in eosinophils and neutrophils, but it is not expressed in peripheral monocytes or lymphocytes. PADI4 catalyzes the citrullination/deimination of arginine residues of proteins. In addition, PADI4 may play an important role in tumourigenesis. Genetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA), which is a systemic inflammatory disease with autoimmune features and a complex genetic component.
Note
For Research Use Only , Not for Diagnostic Use.